Navigation Links
New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

RIDGEFIELD, CT, Sept. 21, 2011 /PRNewswire/ -- Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine (NEJM). IPF is a progressive and severely debilitating lung disease with a high mortality rate, for which there are no approved treatments in the United States.


In the study, known as TOMORROW (To Improve Pulmonary Fibrosis with BIBF 1120), patients treated with 150 mg of BIBF 1120 twice daily demonstrated a 68 percent reduction in the rate of forced vital capacity (FVC) decline compared to placebo. FVC is the volume of air that is expelled into a spirometer following maximum inhalation. FVC, which is a test that measures lung function, is a part of the examinations conducted in IPF patients and is scientifically accepted for assessment of IPF treatment effects. Patients treated with 150 mg of BIBF 1120 twice daily also had a lower incidence of acute exacerbations, defined as sudden deterioration of clinical status, compared with placebo. Acute exacerbations are associated with rapid disease progression, severe abrupt decline in FVC and high mortality.

In addition, treatment with 150 mg of BIBF 1120 twice daily resulted in a small decrease in impairment of quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ). SGRQ scores measure the impact of quality of life, with higher scores – as well as increasing scores – signaling greater impairment. In contrast, increased impairment was reported among patients receiving placebo.

Gastrointestinal symptoms and liver transaminase increases were more frequent in patients receiving 150 mg of BIBF 1120 twice daily than placebo and adverse events leading to discontinuation were mostly diarrhea, nausea and vomiting.

"People who suffer from IPF are in great need of a safe and effective treatment to preserve lung function so they can maintain physical activity and reduce the impact on their independence for as long as possible," said Luca Richeldi, MD, PhD, lead study author and director of the Research Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, Modena, Italy. "The positive trends in slowing the decline in lung function over time, reducing the incidence of acute exacerbations and improving the quality of life with BIBF 1120 are a promising proof of concept."

BIBF 1120 received orphan-drug designation from the U.S. Food and Drug Administration in June 2011. Two pivotal phase III clinical trials are currently underway enrolling a total of 970 patients in 20 countries. The first patients entered the trials in April and May 2011, respectively. For more information about the phase III trials or to learn how to enroll, please visit (identifiers NCT01335464 and NCT01335477).

"The results of the phase II clinical trial for BIBF 1120 in IPF give us the confidence to continue assessing the compound's potential in phase III clinical trials," said Christopher Corsico, MD, MPH, senior vice president, Medicine and Regulatory, North America, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim remains committed to identifying an effective treatment for IPF to help bridge the unmet therapeutic need for the thousands of people suffering from this fatal disease."

TOMORROW Data at ERS 2011 Annual Congress

The NEJM paper will be presented at the European Respiratory Society (ERS) 2011 Annual Congress on Monday, Sept. 26, 2011. Additional results of the TOMORROW trial will be presented during oral sessions at ERS on Sunday, Sept. 25, 2011 and at a BI-sponsored symposium on Monday, Sept. 26, 2011. Key presentations include:

  • Efficacy of BIBF 1120 in patients with IPF is dose-dependent: results from the TOMORROW trial (Sunday, Sept. 25, 2011, 8:30-8:45 a.m. CEST)
  • Effect of baseline FVC on preservation of lung function with BIBF 1120: results from the TOMORROW trial (Sunday, Sept. 25, 2011, 8:45-9 a.m. CEST)
  • Presentation of the NEJM TOMORROW paper; Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis at the ERS/NEJM "Late Breaking Research Session" (Monday, Sept. 26, 2011, 1:18-1:36 p.m. CEST)
  • Satellite symposium: Idiopathic Pulmonary Fibrosis: Evolutions in Diagnosis and Treatment  (Monday, Sept. 26, 2011, 5:15-7:15 p.m. CEST)

About the TOMORROW Trial

The phase II TOMORROW trial was a 12-month, randomized, double-blind, placebo-controlled trial conducted at 92 sites in 25 countries. The trial evaluated the safety and efficacy of oral BIBF 1120 at four dosage levels in reducing decline in lung function measured by FVC among 432 patients diagnosed with IPF, as defined by the American Thoracic Society (ATS) and ERS.

The primary endpoint for the TOMORROW trial was annual rate of decline in FVC. Secondary endpoints included acute exacerbations, quality of life using the SGRQ and total lung capacity.

About BIBF 1120

BIBF 1120 is an investigational small molecule tyrosine kinase inhibitor (TKI) in development by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF). It targets three growth factors: the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). These receptors have been shown to be potentially involved in pathomechanisms of pulmonary fibrosis. By blocking these signaling pathways that are involved in fibrotic processes, it is believed that BIBF 1120 has the potential to reduce disease progression, namely slowing the decline of lung function. BIBF 1120 is also in clinical development as a treatment option for cancer, including non-small cell lung cancer, ovarian cancer, colorectal cancer and hepatocellular carcinoma.

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and severely debilitating lung disease with a high mortality rate, for which there are no approved treatments in the U.S. Research indicates that IPF affects approximately 100,000 Americans. IPF is characterized by inflammation and scarring of lung tissue and loss of lung function over time. Development of scarred tissue is called fibrosis. Over time, as the tissue thickens and stiffens with scarring, the lungs lose their ability to take in and transfer oxygen into the bloodstream, and vital organs do not get enough oxygen. As a result, individuals with IPF experience shortness of breath and often have difficulty participating in everyday physical activities.

Leading Respiratory Forward

Boehringer Ingelheim has been a leader in developing therapies for chronic obstructive pulmonary disease for more than 20 years. Treatment of airway diseases has long been a major area of focus for Boehringer Ingelheim and significant resources are dedicated to research in this field. More recently, the Company has also branched out into developing treatment options for asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit and follow us on Twitter at

Boehringer Ingelheim Pharmaceuticals, Inc.
Emily Baier
Public Affairs & Communications

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
2. Studying Fluid Overflow in Patients With Devices
3. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
4. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
5. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
6. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
7. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
10. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):